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ABSTRACT 
Background – The risk of adverse events in patients with left ventricular non-
compaction cardiomyopathy (LVNC) is substantial. This study was designed to 
determine the prognostic value of NT-proBNP, left ventricular ejection fraction 
(LVEF), NYHA class, and exercise capacity in LVNC patients. 
Methods – Cox regression analyses were performed for evaluating the prognostic 
value of NT-proBNP, LVEF, NYHA class, and exercise capacity on the occurrence of 
death or heart transplantation. 153 patients were included. 
Results – During 1013 person-years (longest follow-up 18.5 years) 23 patients 
(15%) died or underwent heart transplantation. We observed a significant 
relationship of NT-proBNP (adjusted HR 2.44, 95%-CI 1.45-4.09, for every NT-
proBNP doubling, p = 0.0007) and LVEF (adjusted HR for age 60 years: 2.68, 95%-
CI 1.62-4.41, p = 0.0001) with the risk of death or heart transplantation. Combined 
covariate analysis indicated a strong influence of NT-proBNP (adjusted 2.89, 95%-CI 
1.33-6.26, p = 0.007), whereas LVEF was no longer significant (adjusted HR 0.82, 
95%-CI 0.42-1.67, p = 0.66) demonstrating a favorable prognostic power of NT-
proBNP over LVEF. An increase in NYHA class was associated with a worse 
outcome, and exercise capacity revealed a trend in the same direction. For all the 
above mentioned analyses, similar results were obtained when assessing the values 
at first presentation. 
Conclusion – This study provides evidence that an increase in NT-proBNP is a 
strong predictor of outcome in patients with LVNC. The prognostic power of NT-
proBNP is at least as good as that of LVEF, indicating that routine NT-proBNP 
measurement may improve risk assessment in LVNC. 
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INTRODUCTION 
Left ventricular non-compaction cardiomyopathy (LVNC) is a distinct primary 
cardiomyopathy characterized by a thin, compacted, outer (epicardial) layer and a 
thick, non-compacted, inner (endocardial) layer with deep recesses between 
prominent trabeculations(1-3). Since its first description, the awareness of LVNC has 
increased (4, 5). With wider recognition of the disease and systematic family 
screening the number of asymptomatic patients diagnosed with LVNC is increasing. 
Symptomatic patients typically present with heart failure, ventricular arrhythmias or 
thromboembolic events (6-8). However, overall event rates and predictors of 
outcome remain ill defined. Mortality rates in earlier studies range from 2% to 35%, 
over median follow-up periods ranging from 2.3 to 4.5-years (9-13). These studies 
observed an association between presentation with symptoms, reduced left 
ventricular ejection fraction and the risk for adverse outcomes (7, 8, 10-12). 
Nevertheless, quantitative data allowing a reliable assessment of a patient’s risk is 
scarce.  
In cardiomyopathies other than LVNC, parameters like left ventricular ejection 
fraction, heart failure symptoms, and exercise capacity correlate with clinical 
outcome. Due to its low prevalence, the value of such parameters in LVNC is not as 
well defined, and the prognostic relevance of the heart failure marker N-terminal 
fragment of prohormone brain natriuretic peptide (NT-proBNP) as well as that of 
exercise capacity have not been examined so far. 
The aim of this study was to determine the prognostic value of NT-proBNP in 
LVNC patients per se and in comparison with left ventricular ejection fraction (LVEF), 
New York Heart Association (NYHA) functional class, and exercise capacity. In 
addition, clinically established cut-off values (LVEF 55% and LVEF 30%, specified 
standard values for NT-proBNP) as well as cut-off points providing the best 
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prognostic discrimination in regard to death and heart transplantation were 
assessed. 
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METHODS 
Patients 
All patients diagnosed with isolated LVNC between 1988 and 2015, identified 
from the clinical and imaging databases at the University Hospitals Zurich and Basel 
were included in this retrospective analysis. The study was approved by the local 
ethical committees of Zurich and Basel and informed consent was obtained. The 
echocardiographic criteria described by Jenni et al. were applied to establish the 
diagnosis (14).  These criteria include 1) a thickened, two-layered myocardium with a 
compacted outer and a non-compacted inner layer, ratio of systolic thickness of non-
compacted to compacted layer > 2 in parasternal short axis view, 2) color Doppler 
evidence of deep intertrabecular recesses filled with blood from the left ventricular 
cavity, 3) typical distribution of affected segments in the mid-lateral, mid-inferior and 
apical left ventricle, and 4) absence of coexisting cardiac abnormalities for the 
isolated form of the disease.  
Demographical, clinical, and technical (laboratory, exercise test, 
echocardiography) data were collected retrospectively and entered into a web-based 
database (SecuTrial, Berlin, Germany) hosted by the Clinical Trial Center at the 
University of Zurich. 
The endpoint was defined as the occurrence of all-cause death or need for 
heart transplantation as assessed in hospital records as well as by telephone survey. 
 
Prohormone Brain Natriuretic Peptide 
NT-proBNP levels were measured in heparinized blood plasma using the 
Cobas Analyzer (Roche Diagnostics, Basel, Switzerland) at the Institutes of Clinical 
Chemistry of the University Hospital Zurich and University Hospital Basel. Normal 
NT-proBNP values were defined as follows: for males <60 years, ≤100 ng/l; for 
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males ≥60 years, ≤172 ng/l; for females <60 years, ≤164 ng/l; and for females ≥60 
years, ≤225 ng/l (15). 
 
Left Ventricular Ejection Fraction 
Echocardiography studies were performed using commercially available 
equipment (iE33 or Epiq 7, Philips Medical Systems, Andover MA, USA; Vivid7 or 
E9, GE Healthcare, Buckinghamshire, UK; Acuson Sequoia 512, Siemens Medical 
Solutions, Forchheim, Germany). LVEF was determined by the biplane Simpson’s 
method. 
 
NYHA Functional Class 
NYHA functional class data was collected via medical history and assessed as 
previously described (16). 
 
Exercise capacity 
Exercise capacity was determined by bicycle ergometer (Schiller, Switzerland) 
using an individualized ramp protocol and expressed as percent of target 
performance (PoTP). Target performance (Watt) was defined as follows: for males, 
6.773 + (136.141 × BSA) – (0.064 × age) – (0.916 × BSA × age); for females, 3.933 
+ (86.641 × BSA) – (0.015 × age) – (0.346 × BSA × age) (17). BSA (m2) was 
determined as follows: 0.007184 × weight (kg)^0.425 × height (cm)^0.725. 
 
Statistical analysis 
Statistical analysis of the time-to-event data was performed using Cox proportional 
hazard models with age as time scale (with or without adjustment for specific 
variables as stated in the results part), so patients were treated as left-truncated at 
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their age of entry. In order to check for non-informative late entry, the age at entry of 
a patient was included in the adjusted models, without showing a significant effect 
(18). Time-dependent variation of the covariates LVEF, NT-proBNP, NYHA class, 
and PoTP was taken into account by creating a data set listing the time-dependent 
covariates for each follow-up visit of a patient and the time span during which the 
values of the covariates did not change (19). In case of violation of the proportional 
hazards assumption, examined by plotting the scaled Schoenfeld residuals against 
time (age of patients) and by applying the test developed by Grambsch and 
Therneau (20), the covariate was modeled using a time-dependent coefficient (linear 
time scale), and hazard ratios were assessed for different ages separately. Entry into 
study was defined as the first visit in one of the two study hospitals when at least one 
parameter was recorded; end of data acquisition for the study was 19.04.2015 
(retrieval of data set).  
To determine a cut-off value, we used the minimum p-value approach (21), i.e., we 
fitted a Cox regression model at each observation of a restricted set of all potential 
cut points. Using the p-value of the group comparison (above and below the cut 
point) as selection criterion, the cut point resulting in the smallest p-value was taken. 
The p-value, the estimated log-hazard ratio (HR) and its standard error were 
corrected for multiple testing (22). In the analysis of different cut-offs, we considered 
a minimum of two events per group necessary to avoid complete separation, i.e., a 
split where all events are exclusively in one group. NT-proBNP values were 
transformed by taking the binary logarithm in order to attain a symmetric distribution. 
As statistical software, we used the R programming language. 
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RESULTS 
Patients 
During 1013 person-years (longest follow-up 18.5 years) 23 patients (15%) died 
or underwent heart transplantation. An overview of the study population, patient 
groups, measurements, follow-up, and outcome is provided in Table 1.  
 
Prohormone Brain Natriuretic Peptide 
The median NT-proBNP level in all non-event associated measurements (all 
values except event-preceding values) was 292 ng/l. Median NT-proBNP level at the 
last measurement preceding an event was 6416 ng/l (Figure 1A).  
Cox regression revealed a highly significant relationship between NT-proBNP 
level (log2 transformed) and the risk of death or heart transplantation. This 
dependency was observed both in the unadjusted analysis (HR 2.37, 95%-CI 1.49-
3.76, p=0.0003) and after adjustment for age and gender (adjusted HR 2.44, 95%-CI 
1.45-4.09, p = 0.0007, Figure 1C).  
Next, the prognostic values of normal NT-proBNP levels, NT-proBNP levels 
above 2000 ng/l, and NT-proBNP levels above 10000 ng/l were assessed. No event 
was recorded in patients with NT-proBNP levels in the normal range indicating an 
excellent prognosis for these patients (Figure 1D). In contrast, NT-proBNP levels 
higher than 2000 ng/l were associated with a very poor prognosis. This threshold 
provided the best prognostic discrimination with a hazard ratio of 40.2 adjusted for 
age and gender (95%-CI 5.57-289, p <0.0001, Figure 1D) with respect to death or 
heart transplantation using Cox regression models and the minimum p-value 
method. NT-proBNP levels of more than 10000 ng/l were associated with an 
adjusted hazard ratio of 14.8 (95%-CI 1.75-125.31, p=0.003). 
Table 1: Overview of patient groups, measurements, and follow-up 
 All patients NT-proBNP LVEF NYHA PoTP 
Number of patients 153 87 148 105 86 
Number of measurements 1462 290 535 437 200 
      
Age at entry (years; mean ±SD) 43 ±19.4 47 ±17.5 43 ±19.1 43 ±19.0 42 ±16.7 
Male sex (%) 91 (59.5) 56 (64.4) 87 (58.8) 69 (65.7) 58 (67.4) 
      
Follow-up (days; median, IQR) 2193 (888-3721) 1775 (1015-2861) 3264 (1447-4280) 3057 (1199-4209) 2320 (934-3828) 
Death (%) 15 (9.9) 11 (12.6) 15 (10.1) 12 (11.4) 7 (8.1) 
Heart transplantation (%) 8 (5.2) 4 (4.6) 7 (4.7) 5 (4.8) 4 (4.7) 
Death or heart transplantation (%) 23 (15.1) 15 (17.2) 22 (14.8) 17 (16.2) 11 (12.8) 
Age at endpoint (years; mean ±SD) 63 ±16.2 61 ±17.2 63 ±16.3 61 ±17.3 55 ±15.9 
 
Number of patients in which specific parameters were assessed, and number of measurements per parameter. Follow-up duration, 
number of deaths and heart transplantations, and age at time of death or heart transplantation for each group of patients in which a 
specific parameter was assessed. NT-proBNP = N-terminal fragment of prohormone brain natriuretic peptide; LVEF = left ventricular 
ejection fraction; NYHA = New York Heart Association functional class; PoTP = percent of target performance.
To assess the prognostic value of NT-proBNP levels at initial presentation, we 
performed a Cox regression analysis including only the values at first presentation as 
covariates. HRs of initial NT-proBNP levels with respect to death or heart 
transplantation were as follows: unadjusted HR 1.8, 95%-CI 1.46-2.22, p<0.0001; 
adjusted for age and gender HR 1.69, 95%-CI 1.35-2.10, p<0.0001.  
 
Left Ventricular Ejection Fraction  
Median LVEF in all non-event related measurements was 45%. Median LVEF 
at the last measurement before an event was 21% (Figure 1B).  
A Cox regression analysis revealed a highly significant relationship between 
decrease in LVEF and the risk of death or heart transplantation. Allowing for a time-
dependent effect of LVEF, the HR is decreasing with age, adjusted for age at study 
entry and gender (age 30 years: HR 6.14 for every 10% decrease, 95%-CI 1.84-
20.59, p = 0.003; age 40 years: HR 4.68, 95%-CI 1.82-12.00, p = 0.001; age 50 
years: HR 3.51, 95%-CI 1.76-7.10, p = 0.0004; age 60 years: HR 2.68, 95%-CI 1.62-
4.41, p = 0.0001; age 70 years: HR 2.02, 95%-CI 1.33-3.07, p = 0.001; Figure 1C) 
and unadjusted (supplemental material). 
The prognostic value of an LVEF >55% or <30%, respectively, was also 
assessed. Only one event was recorded in patients with an LVEF >55%, indicating 
an excellent prognosis for this patient group. In contrast, an LVEF <30% was 
associated with a hazard ratio of 8.52 adjusted for age and gender (95%-CI 2.82-
25.75, p<0.0001, Figure 1D). An LVEF of 15% provided the best prognostic 
discrimination (HR adjusted for age and gender 12.58, 95%-CI 3.51-45.1, p<0.0001, 
Figure 1D) using Cox regression models and the minimum p-value method, 
indicating a very poor prognosis for patients with an LVEF below this value. 
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To assess the prognostic value of LVEF at initial presentation, we performed a 
Cox regression analysis including the values at first presentation only. This analysis 
provided similar results as the analysis using time-dependent covariates. Hazard 
ratios of initial LVEF (per 10% decrease) were as follows: unadjusted HR 2.07, 95%-
CI 1.50-2.87, p <0.0001; HR adjusted for age and gender 1.67, 95%-CI 1.11-2.30, p 
= 0.007.  
 
Combined Covariate Analysis of NT-proBNP and LVEF 
Bivariate analysis of the linear relationship of NT-proBNP (log2 transformed) 
and LVEF revealed a moderate to strong negative correlation (Pearson’s r = -0.68, 
Figure 2A). Similar results were obtained after the data had been weighted with 
weights equal to the time span during which the values of both covariates did not 
change (weighted r = -0.59, Figure 2B). 
To compare the prognostic value of NT-proBNP to that of LVEF, a Cox 
regression model was fitted using NT-proBNP and LVEF as covariates. NT-proBNP 
exhibited a very strong influence on the risk of death or heart transplantation (HR 
2.69, 95%-CI 1.34-5.41, p = 0.005), whereas LVEF did no longer seem to be related 
(HR 0.82, 95%-CI 0.42-1.67, p = 0.67, Figure 2C) indicating collinearity of the two 
parameters with favorable prognostic power of NT-proBNP over LVEF. A similar 
effect was observed after adjustment for age at study entry (NT-proBNP: adjusted 
HR 2.89, 95%-CI 1.33-6.26, p = 0.007; LVEF: adjusted HR 0.82, 95%-CI 0.42-1.67, 
p = 0.66). 
To compare the prognostic value of NT-proBNP and LVEF at initial 
presentation, we also performed an analysis using only the initial values of NT-
proBNP and LVEF as covariates. Initial NT-proBNP level exhibited a strong impact 
on the risk of death or heart transplantation (HR 1.69, 95%-CI 1.27-2.24, p = 
March 1, 2018  14/26 
0.0003), whereas LVEF was no longer related (HR 1.22 95%-CI 0.68-2.30, p = 0.50), 
indicating that the initial values also exhibit collinearity with favorable prognostic 
power of NT-proBNP over LVEF. After adjustment for age at study entry, however, 
there was no evidence for a difference in prognostic power between the two 
parameters.  
 
NYHA Functional Class 
Among all the non-event related measurements, 12.3% were in NYHA class III 
or IV (NYHA classes III and IV merged due to only a single patient in NYHA class 
IV). At the last assessment preceding an event, 29.4% of patients were in NYHA 
class III or IV (Figure 3A).  
An increase in NYHA class was associated with a worse outcome, both 
unadjusted (HR 3.48, 95%-CI 1.57-7.75, p = 0.002) and adjusted for age and gender 
(HR 3.58, 95%-CI 1.57-8.15, p = 0.002, Figure 1C). Comparing the different NYHA 
classes among each other revealed the following adjusted hazard ratios: NYHA III/IV 
vs. NYHA I: HR 12.05, 95%-CI 2.04-71.32, p = 0.006; NYHA III/IV vs. NYHA II: HR 
3.05, 95%-CI 0.87-10.71, p = 0.082; NYHA II vs. NYHA I: HR 3.95, 95%-CI 0.80-
19.49, p = 0.091. There were no classes without an event (NYHA class I, 2 events; 
NYHA class II, 10 events; NYHA class III/IV, 5 events). 
 
Exercise capacity 
Median PoTP in all non-event related measurements was 89% (Figure 3B). The 
median PoTP at the last assessment before an event was 56%. A Cox model, 
adjusted for age at study entry and gender and allowing for a time-dependent effect 
of PoTP revealed for the age of 30, 40, and 50 years a significant relationship of 
decreasing PoTP and the risk of death or heart transplantation. There was no 
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evidence for such an association for the age of 60 and 70 years. Age 30 years: HR 
12.15 for every 10% decrease, 95%-CI 1.65-45.27, p = 0.014; age 40 years: HR 
5.65, 95%-CI 1.38-22.95, p = 0.016; age 50 years: HR 2.6, 95%-CI 1.14-5.93, p = 
0.023; age 60 years: HR 1.20, 95%-CI 0.86-1.67, p = 0.28; age 70 years: HR 0.55, 
95%-CI 0.33-0.92, p = 0.024 (Figure 1C). Unadjusted analysis revealed an 
analogous result (supplemental material). 
Cox regression models and the minimum p-value method were used to 
determine the cut-off point with the best prognostic discrimination. A value of 56% 
provided the best discrimination for PoTP between patients with and without events 
(HR 6.679, 95%-CI 1.98-22.52, p = 0.003). PoTP at initial presentation was also 
assessed but did not generate additional prognostic information (unadjusted HR 
0.99, p = 0.20; HR adjusted for age and gender 0.99, p = 0.51). 
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DISCUSSION 
The predictors of mortality remain ill-defined in patients with LVNC. This study 
determined the prognostic value of NT-proBNP in comparison with other markers of 
left ventricular function such as LVEF, NYHA functional class, and exercise capacity 
in the largest LVNC cohort published to date, with 153 patients and a median follow-
up duration of more than 6 years. The overall mortality and heart transplantation rate 
in our cohort was 15%, which is in the range of previous studies reporting rates 
between 2% and 35% (9-13). 
 
Prognostic value of NT-proBNP and LVEF 
NT-proBNP was an extremely strong marker of death or heart transplantation in 
LVNC patients. Not a single case of death or heart transplantation was recorded in 
patients with normal NT-proBNP levels, indicating an excellent prognosis in such 
individuals. In contrast, every doubling of NT-proBNP was associated with a 2.4-
times higher and a NT-proBNP level >2000 ng/l with a 40-times higher risk, 
respectively, of death or heart transplantation. A higher cut-off value did not lead to 
additional prognostic power, suggesting that the manifestation of ventricular 
dysfunction and heart failure as such rather than the degree of congestion within the 
pathologic range is associated with a poor prognosis. This interpretation is consistent 
with the observation that LVNC patients with symptoms of heart failure have a worse 
prognosis when compared to asymptomatic patients (10). An association of elevated 
NT-proBNP levels and worse clinical outcome has been documented for dilated 
cardiomyopathy (23), hypertrophic cardiomyopathy (24), and hypertensive heart 
disease (25), indicating that the level of natriuretic peptide mainly reflects the degree 
of left ventricular dysfunction rather than representing a specific type of 
cardiomyopathy.  
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Similar to previous reports in smaller cohorts (7-12), LVNC patients exhibiting 
an impaired left ventricular systolic function were at higher risk of death or heart 
transplantation in this study. Only a single death (acute circulatory failure of unknown 
cause at the age of 84 years) occurred in the patient group with an LVEF ≥55%, 
indicating a very good prognosis in patients with an ejection fraction in the normal 
range. In contrast, every reduction of LVEF was associated with a significantly higher 
risk of death or heart transplantation. This effect was consistent amongst all ages 
with the strongest effect at young age. A possible reason for this observation is that 
older patients have more comorbidities which influence the risk of death irrespective 
of LVEF. Average age at death or heart transplantation was 63 years, thus the 
hazard ratio for the age 60 is presented in figure 1C. In line with previous 
observations (10), a similar impact of LVEF on mortality was observed when 
examining the values at initial presentation.  
In a Cox regression model using both NT-proBNP and LVEF as covariates, NT-
proBNP exhibited a very strong influence on the risk of death or heart transplantation 
whereas LVEF was not significant, indicating a favorable prognostic power of NT-
proBNP over LVEF. This finding indicates that NT-proBNP may be more useful than 
LVEF for predicting outcome in LVNC. This superiority was observed in the time-
dependent covariate analysis as well as in the unadjusted analysis of values at initial 
presentation. Hence, NT-proBNP is useful not only for risk assessment when the 
patient is seen for the first time but particularly during follow-up. Similar observations 
have been made in patients with congestive heart failure (26). The prognostic 
superiority of NT-proBNP over that of LVEF may result from the different profile of 
cardiovascular responses that the two parameters reflect; while LVEF represents left 
ventricular systolic impairment, NT-proBNP detects both left ventricular and right 
ventricular dysfunction as well as elevated pulmonary pressure (27). A conceivable 
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additional explanation is that NT-proBNP is a standardized laboratory parameter with 
very high accuracy (28), while echocardiographic assessment of LVEF is dependent 
on the investigator’s experience and image quality, and its accuracy is an ongoing 
controversial debate (29).  
 
Prognostic value of NYHA functional class and exercise capacity 
An increase in NYHA functional class was associated with a 3.6-times 
increased risk of death or heart transplantation, both in a time-dependent covariate 
analysis and when examining the values at initial presentation, confirming findings 
from previous smaller LVNC studies (8, 10-12) and unselected heart failure patients 
(30) as well. This finding is of clinical interest since information on NYHA class is 
easily collected and can be monitored autonomously by the patient. However, in 
contrast to NT-proBNP, NYHA class is a subjective, semi-quantitative parameter with 
only 4 stages and is known to be much less specific than NT-proBNP for detecting 
congestive heart failure (31). 
A decrease in exercise capacity measured as percentage of target performance 
was associated with a higher risk of death or heart transplantation for ages up to 50 
years. The observed decrease of the effect with age could be due to the fact that 
PoTP is less frequently measured in this population and comorbidities influencing the 
risk of death are more common. In addition, PoTP does not only depend on cardiac 
function, but also on pulmonary function, the musculoskeletal system, and patient 
motivation. Peak oxygen consumption which was not available in most of the 
patients would possibly have been a more sensitive marker (32).  
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Study limitations 
Even though the present study represents the largest LVNC cohort ever 
studied, it is still limited by the relatively small number of patients as compared to 
more common diseases, by the referral bias, and – given the observational 
retrospective study design – by a possible confounding bias as well as the problem 
of informative but missing measurements of patients not requiring medical care. 
 
Conclusion 
This study provides evidence that an increase in NT-proBNP is associated with 
a higher risk of death or heart transplantation in patients with LVNC. Furthermore, 
NT-proBNP is an extremely strong prognostic marker with a prognostic power at 
least as good as that of LVEF. This finding may have implications on the 
development of cost-effective risk assessment and treatment strategies in LVNC 
patients since NT-proBNP is a standardized laboratory parameter from a regular 
blood sample. Based on the present findings in this large LVNC cohort, regular 
measurement of NT-proBNP may improve risk stratification and influence follow-up 
intervals in patients with this rare cardiomyopathy. 
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FIGURE LEGENDS 
Figure 1A: NT-proBNP over time and before an event (death or heart 
transplantation) 
Dot plot charts representing values of NT-proBNP measurements over time except 
event-preceding measurements (n = 275) in all patients, and event-preceding 
measurements (n = 15) in patients reaching the endpoint. The horizontal line 
indicates the median value. The y-axis is depicted in a log2-scale. NT-proBNP = N-
terminal fragment of prohormone brain natriuretic peptide. 
 
Figure 1B: Left ventricular ejection fraction over time and before an event 
(death or heart transplantation)  
Dot plot charts representing values of left ventricular ejection fraction measurements 
over time except event-preceding measurements (n = 513) in all patients and event-
preceding measurements (n = 22) in patients reaching the endpoint. The horizontal 
line indicates the median value.  
 
Figure 1C: Hazard ratios of different parameters in terms of death or heart 
transplantation 
Hazard ratios, adjusted for age and gender, with 95% confidence intervals. HR for 
every doubling of NT-NT-proBNP, for every 10% decrease in LVEF (age 60 years), 
for every increase in NYHA functional class, and for every 10% decrease in PoTP 
(age 60 years). LVEF = left ventricular ejection fraction; NYHA = New York Heart 
Association functional class; PoTP = percent of target performance; NT-proBNP = N-
terminal fragment of prohormone brain natriuretic peptide. 
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Figure 1D: Hazard ratios of different NT-proBNP and LVEF cut-offs in terms of 
death or heart transplantation 
Hazard ratios, adjusted for age and gender, with 95% confidence intervals depicted 
on a log10-scale. No events were recorded in patients exhibiting normal NT-proBNP 
levels, HR not quantifiable (*); HR for NT-proBNP values >2000 ng/l. Only one event 
was observed in patients with an LVEF >55%, HR not quantifiable (*); HR for LVEF 
<30%; HR for LVEF <15%. LVEF = left ventricular ejection fraction; NT-proBNP = N-
terminal fragment of prohormone brain natriuretic peptide. 
 
Figure 2A: Scatter plot of LVEF and NT-proBNP (log2) measurements 
The red points depict the last measurements before death or heart transplantation. 
The Pearson correlation coefficient is shown in the lower left corner. A regression 
line is depicted, indicating a moderate to strong negative correlation of NT-proBNP 
(log2) and LVEF. The plot ignores the grouping of the measurements within the 
patients. LVEF = left ventricular ejection fraction; NT-proBNP = N-terminal fragment 
of prohormone brain natriuretic peptide. 
 
Figure 2B: Scatter plot of LVEF and NT-proBNP measurements weighted for 
length of observation time 
The red points depict the last measurements before death or heart transplantation. 
The area of the circles is proportional to their weight with respect to the length of 
observation time (maximum observation time has an attributed weight of 1). The 
weighted Pearson correlation coefficient is shown in the lower left corner. A weighted 
regression line is depicted. All observations above the line represent increased NT-
proBNP values compared to the expected average. The plot ignores the grouping of 
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the measurements within the patients. LVEF = left ventricular ejection fraction; NT-
proBNP = N-terminal fragment of prohormone brain natriuretic peptide. 
 
Figure 2C: Hazard ratios of LVEF and NT-proBNP as combined covariates in 
terms of death or heart transplantation 
Unadjusted and adjusted (for age) hazard ratios with 95% confidence intervals using 
LVEF and NT-proBNP as covariates simultaneously. HR for every doubling of NT-
proBNP and for every 10% decrease in LVEF, indicating a strong influence of NT-
proBNP on outcome, whereas LVEF is no longer significant, demonstrating a 
favourable prognostic power of NT-proBNP. LVEF = left ventricular ejection fraction; 
NT-proBNP = N-terminal fragment of prohormone brain natriuretic peptide. 
 
Figure 3A: New York Heart Association class distribution over time and before 
an event (death or heart transplantation) 
Distribution of NYHA functional class over time except event-preceding values (n = 
420) in all patients and distribution of event-preceding NYHA classes (n = 17) in 
patients reaching the endpoint. NYHA = New York Heart Association functional 
class. 
 
Figure 3B: Percent of target performance (PoTP) over time and before an event 
(death or heart transplantation)  
Box plots representing values of PoTP in a bicycle ergometer test over time except 
event-preceding values (n = 189) in all patients and event-preceding measurements 
(n = 11) in patients reaching the endpoint. PoTP = percent of target performance.  
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